CBIOCrescent Biopharma, Inc.
$14.92+24% 1Y
$14.92
$8.9452 weeks$26.98
Price
+24%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 3% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for CBIO today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$388.8M
1 year+24%
5 years-106%
Charts
As reported to the SEC, without any scoring.
Crescent Biopharma, Inc. (CBIO) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $25M. For the full year FY2025, revenue was $11M and net income −$154M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 15, 2026On July 14, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and …Other event · Form 8-K
- Dec 4, 2025Strategic Transaction with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. On December 2, 2025, Crescent Biopharma Operating Company, LLC (“Crescent OpCo”), the wholly owned subsidiary of Crescent Biopharma, Inc., a Cayman Islands exempted company (together with its subsidiaries, “Crescent” or the “Company”) …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.